NCT00144300 - Ophthalmologic Safety Study of Pramipexole Immediate Release (IR) Versus Ropinirole in Early Parkinson's Disease (PD) Patients | Biotech Hunter

Enrollment

246

Participants

Timeline

Start Date

January 31, 2005

Primary Completion Date

September 30, 2010

Conditions

Parkinson Disease

Interventions

DRUG

Mirapex

Standard marketed product dispensed according to manufacturer's guidelines

DRUG

Requip

Standard marketed product dispensed according to manufacturer's guidelines

Trial Locations (21)

248.538.00007 Boehringer Ingelheim Investigational Site, Birmingham

248.538.00008 Boehringer Ingelheim Investigational Site, Little Rock

248.538.00021 Boehringer Ingelheim Investigational Site, Fountain Valley

248.538.00022 Boehringer Ingelheim Investigational Site, Los Angeles

248.538.00001 Boehringer Ingelheim Investigational Site, New Haven

248.538.00002 Boehringer Ingelheim Investigational Site, Miami

248.538.00016 Boehringer Ingelheim Investigational Site, Tampa

248.538.00023 Boehringer Ingelheim Investigational Site, Tampa

248.538.00013 Boehringer Ingelheim Investigational Site, Atlanta

248.538.00009 Boehringer Ingelheim Investigational Site, Augusta

248.538.00011 Boehringer Ingelheim Investigational Site, Chicago

248.538.00005 Boehringer Ingelheim Investigational Site, Baltimore

248.538.00014 Boehringer Ingelheim Investigational Site, Southfield

248.538.00010 Boehringer Ingelheim Investigational Site, New York

248.538.00015 Boehringer Ingelheim Investigational Site, New York

248.538.00020 Boehringer Ingelheim Investigational Site, New York

248.538.00012 Boehringer Ingelheim Investigational Site, Charlotte

248.538.00006 Boehringer Ingelheim Investigational Site, Philadelphia

248.538.00004 Boehringer Ingelheim Investigational Site, Memphis

248.538.00003 Boehringer Ingelheim Investigational Site, Houston

248.538.00017 Boehringer Ingelheim Investigational Site, Morgantown